What is A&G Pharmaceutical?
A&G Pharmaceutical operates at the intersection of therapeutic development and diagnostic precision, specializing in the field of theranostics. The company is primarily focused on the engineering of monoclonal antibodies designed to target specific cancer biomarkers. By integrating therapeutic intervention with FDA-approved companion diagnostics, A&G Pharmaceutical facilitates a more personalized approach to oncology, enabling clinicians to monitor treatment efficacy in real-time. This dual-modality strategy is designed to optimize patient outcomes while addressing the critical need for early detection and targeted tumor suppression in aggressive cancer phenotypes.
How much funding has A&G Pharmaceutical raised?
A&G Pharmaceutical has raised a total of $387K across 2 funding rounds:
Debt
$150K
Debt
$237K
Debt (2020): $150K with participation from PPP
Debt (2021): $237K led by PPP
Key Investors in A&G Pharmaceutical
PPP
Public-Private Partnership
What's next for A&G Pharmaceutical?
With this late-stage funding secured, A&G Pharmaceutical is well-positioned to accelerate its pipeline development and expand its footprint in the personalized medicine market. The strategic roadmap likely involves scaling manufacturing capabilities for its monoclonal antibody portfolio and deepening collaborations with major healthcare providers to ensure broader clinical adoption. As the company transitions toward commercialization, the focus will shift from research-heavy development to market penetration and the optimization of its diagnostic-therapeutic ecosystem. Sustained growth will depend on the successful execution of late-stage clinical trials and the continued validation of its biomarker-driven treatment protocols in diverse patient populations.
See full A&G Pharmaceutical company page
